Myelodysplastic Syndromes

FDA Grants Breakthrough Therapy Designation for Pevonedistat to Treat Higher-Risk MDS
July 30, 2020

Takeda Pharmaceutical Company Limited announced the FDA granted pevonedistat, its investigation NEDD8-activating enzyme inhibitor, breakthrough therapy designation to treat patients with higher-risk myelodysplastic syndrome.

FDA Approves Oral Combo of Decitabine and Cedazuridine for Myelodysplastic Syndromes
July 07, 2020

The FDA has approved an oral combination of decitabine and cedazuridine for adult patients with myelodysplastic syndromes.

FDA Approves Luspatercept to Treat Anemia in Patients with Lower-Risk MDS
April 06, 2020

The FDA approved the first and only erythroid maturation agent for the treatment of anemia in patients with lower-risk myelodysplastic syndromes.